Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston ...

Two and a half years later, Musk appears close to pulling off a minor miracle: The company, now called X, may once again be worth about what he paid for it. Bloomberg on Wednesday reported that X ...

To that end, Florida Tech has relaunched the underutilized Center for Advanced Manufacturing and Innovative Design as Vertex, a new "applied innovation hub." Rather than function as a traditional ...

Hours after Elon Musk’s AI company xAI released the latest version of its AI model, Grok 3, X has significantly hiked the price for its top Premium+ subscription plan, which gives users access ...